// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























1151 Abstracts

Coexisting Myasthenia Gravis and Sjogren s Syndrome Patients at Virginia Commonwealth University

Kelly Gwathmey - American Academy of Neurology (AAN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Sjogren's syndrome

Hydroxychloroquine

Frequency Persistence and Patient reported Outcomes of Neurological Symptoms in Mild COVID 19 Results from the ALBERTA HOPE COVID 19 Trial

Aravind Ganesh - American Academy of Neurology (AAN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

Hydroxychloroquine

Primary adrenal insufficiency due to bilateral adrenal hemorrhage-adrenal infarction in a patient with systemic lupus erythematosus and antiphospholipid syndrome

Katerina Bouki - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Lupus

Hydroxychloroquine

Effect of Hydroxychloroquine on Endothelial Function in Older Adults with Moderate-Severe Sleep Apnea: A Randomized Clinical Trial

Leticia Maria Tedesco Silva - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Sleep apnoea

Hydroxychloroquine

A NOVEL PATHOGENIC VARIANT IN ZNF462 GENE ASSOCIATED WITH WEISS-KRUSZKA SYNDROME AND SLE

M. Constantinou - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Thrombotic thrombocytopenic purpura

Hydroxychloroquine

ABATACEPT VERSUS HYDROXYCHLOROQUINE IN PALINDROMIC RHEUMATISM: A MULTICENTER RANDOMIZED CLINICAL TRIAL (PALABA STUDY): TRIAL DESIGN AND PATIENTS CHARACTERISTICS

B. Frade-Sosa - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

Hydroxychloroquine

ADHERENCE TO MEDICATIONS DURING PREGNANCY IN SYSTEMIC AUTOIMMUNE DISEASE

D. Zucchi - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Depression

Hydroxychloroquine

ADVERSE PREGNANCY OUTCOMES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: THE ROLE OF THERAPY.

M. B. Cilona - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

ALL-CAUSE MORTALITY IN PATIENTS WITH PALINDROMIC RHEUMATISM: A POPULATION-BASED COHORT STUDY

H. H. Chen - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic inflammatory myopathies

Hydroxychloroquine

ANTIBODIES AGAINST MODIFIED PROTEIN/PEPTIDE SPECIFICITIES IN RECENT-ONSET PALINDROMIC RHEUMATISM MAY DETERMINE THE EVOLUTION TO RHEUMATOID ARTHRITIS

C. Garca-Moreno - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

ASSESSING TREATMENT PATTERNS WITH DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND PREDNISONE FOR PSORIATIC ARTHRITIS BY RACE/ETHNICITY

F. Ahmed - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

Hydroxychloroquine

ASSESSMENT OF WORK CAPACITY AND PRODUCTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

M. Fominykh - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

ASSOCIATION BETWEEN CUMULATED HYDROXYCHLOROQUINE IN SYSTEMIC LUPUS ERYTHEMATOSUS AND DEVELOPMENT OF CARDIAC CONDUCTION ALTERATIONS: A MULTIPLE LOGISTIC REGRESSION ANALYSIS

A. Herrero-Morant - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Lupus

Hydroxychloroquine

ASSOCIATION BETWEEN PRECONCEPTION COMPLEMENT LEVELS AND USE OF HYDROXYCHLOROQUINE WITH PREGNANCY OUTCOME IN PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME AND CARRIERS OF ANTIPHOSPHOLIPID ANTIBODIES: AN INTERNATIONAL MULTICENTER STUDY

D. Lini - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Antiphospholipid syndrome

Hydroxychloroquine

ASSOCIATION BETWEEN TREATMENT GOAL ACHIEVEMENT AND GRIT PERSONALITY CHARACTERISTICS OF ATTENDING PHYSICIAN IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A MULTICENTER CROSS-SECTIONAL STUDY

K. E. Sada - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

ASSOCIATION OF SEROLOGICAL STATUS WITH THE FREQUENCY OF CLINICAL AND RADIOLOGICAL REMISSION IN RHEUMATOID ARTHRITIS

O. Iaremenko - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

ASSOCIATION OF THE BIOMARKERS SOLUBLE ST2, GALECTIN-3, N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE, PENTRAXIN WITH MYOCARDIAL DYSFUNCTION DETECTED BY SPECKLE TRACKING ECHOCARDIOGRAPHY IN PATIENTS WITH RHEUMATOID ARTHRITIS PRIOR TO BIOLOGICAL THERAPY

I. Kirillova - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Myocardial Dysfunction

Hydroxychloroquine

BARICITINIB AND PULSE STEROIDS COMBINED TREATMENT IN SEVERE COVID-19 PNEUMONIA: PRELIMINARY DATA FROM A RHEUMATOLOGIC EXPERIENCE IN INTENSIVE CARE UNIT

F. Ferro - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Severe COVID-19 pneumonia

Hydroxychloroquine

CERTOLIZUMAB-PEGOL, ABATACEPT, TOCILIZUMAB OR ACTIVE CONVENTIONAL THERAPY IN EARLY RHEUMATOID ARTHRITIS: CLINICAL AND RADIOGRAPHIC 48-WEEKS RESULTS OF THE INVESTIGATOR-INITIATED RANDOMIZED NORD-STAR TRIAL

M. stergaard - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Rheumatoid arthritis

Hydroxychloroquine

CLINICAL EFFICACY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

G. Tarasova - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

Copyright © 2026. QuantiNova All rights reserved